Performance of the AmpliSeq next-generation sequencing (NGS) panel in thyroid nodules with indeterminate cytology
Authors' conclusion
The performances of the AmpliSeq panel are promising; however, the NPV is not sufficient to avoid diagnostic surgery in cytologically indeterminate thyroid nodules.
Study context
- Population
- Patients with cytologically indeterminate thyroid nodules (Bethesda III, IV and V) with routine fine-needle aspiration (FNA) for molecular testing and available final histological diagnosis
- Participants
- 121 patients
- Comparison
- AmpliSeq NGS panel vs final histological diagnosis
- Outcome
- NPV of malignancy of the AmpliSeq panel in Bethesda III and IV thyroid nodules
Methodological detailsretrospective, monocentric
- Retrospective
- Monocentric
Performance
As reported in the abstract
| Test or model | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
| Panel | 55.0% (95% CI: 31.5; 76.9) | 76.9% (95% CI: 66.0; 85.7) | 37.9% (95% CI: 25.7; 51.9) | 87.0% (95% CI: 80.2; 91.7) |
Panel
Sensitivity55.0% (95% CI: 31.5; 76.9)
Specificity76.9% (95% CI: 66.0; 85.7)
PPV37.9% (95% CI: 25.7; 51.9)
NPV87.0% (95% CI: 80.2; 91.7)
Further findings
Histology and molecular results, overall cohort
- Benign nodules on histology
- 86
- Malignant nodules on histology
- 35
- Positive molecular result
- 40
Original publication
Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology. Eur Thyroid J. Published 4 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →